Prognostic value of cytokeratins and carcinoembryonic antigen expression in primary surgically treated cervical cancer.
In a previous study we have shown the prognostic value of expression of cytokeratins and carcinoembryonic antigen (CEA) in cervical cancer FIGO stage III. The present study was performed to evaluate the prognostic value of cytokeratins and CEA in patients with cervical primary cancer stage IB to IIB, surgically treated by radical hysterectomy and lymphadenectomy. Seventy-six patients were included in the study. By application of immunohistochemistry we found AE1/AE3 (cytokeratins) expression in 27 (35.5%) cases and CEA expression in 56 (73.7%) cases. Multivariate analysis for the end points of relapse-free survival and overall survival showed that neither AE1/AE3 expression nor CEA expression had a prognostic value in the studied population. In contrast to patients with primary irradiated cervical carcinoma FIGO stage III, patients with primary surgically treated tumors stage IB to IIB showed no significant prognostic value of cytokeratin or CEA expression of the tumor.
Kainz
C
C
Department of Gynecology & Obstetrics, University of Vienna, Austria.
Zeisler
H
H
Kohlberger
P
P
Gitsch
G
G
Heinzl
H
H
Breitenecker
G
G
Reinthaller
A
A
D014408:Biomarkers, Tumor / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis*; D008197:Lymph Node Excision; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D012008:Recurrence; D012044:Regression Analysis; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery*
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D007633:Keratins